Aristides Capital LLC Invests $81,000 in Heron Therapeutics, Inc. (NASDAQ:HRTX)

Aristides Capital LLC purchased a new stake in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) during the fourth quarter, Holdings Channel reports. The fund purchased 52,849 shares of the biotechnology company’s stock, valued at approximately $81,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Nicolet Advisory Services LLC bought a new position in Heron Therapeutics during the fourth quarter valued at about $25,000. Argent Advisors Inc. bought a new stake in shares of Heron Therapeutics during the 4th quarter worth about $31,000. Y Intercept Hong Kong Ltd acquired a new position in shares of Heron Therapeutics during the 3rd quarter valued at about $39,000. Cutter & CO Brokerage Inc. raised its stake in shares of Heron Therapeutics by 69.6% in the 4th quarter. Cutter & CO Brokerage Inc. now owns 33,135 shares of the biotechnology company’s stock valued at $51,000 after acquiring an additional 13,600 shares in the last quarter. Finally, Intech Investment Management LLC bought a new position in shares of Heron Therapeutics in the 3rd quarter valued at approximately $72,000. Institutional investors and hedge funds own 80.01% of the company’s stock.

Heron Therapeutics Stock Down 6.7 %

Shares of NASDAQ HRTX opened at $1.96 on Tuesday. Heron Therapeutics, Inc. has a 12 month low of $1.04 and a 12 month high of $3.93. The company has a market cap of $298.57 million, a P/E ratio of -10.89 and a beta of 1.39. The business’s 50 day moving average is $2.05 and its two-hundred day moving average is $1.79.

Heron Therapeutics (NASDAQ:HRTX) last released its earnings results on Thursday, February 27th. The biotechnology company reported $0.02 EPS for the quarter, beating the consensus estimate of ($0.03) by $0.05. The company had revenue of $40.78 million for the quarter, compared to analyst estimates of $37.37 million. Sell-side analysts expect that Heron Therapeutics, Inc. will post -0.13 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have issued reports on HRTX. StockNews.com cut Heron Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, March 8th. Needham & Company LLC reiterated a “buy” rating and issued a $4.00 target price on shares of Heron Therapeutics in a research note on Friday, February 28th.

Heron Therapeutics Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.